Cargando…

Dual-Wavelength Imaging of Tumor Progression by Activatable and Targeting Near-Infrared Fluorescent Probes in a Bioluminescent Breast Cancer Model

Bioluminescence imaging (BLI) has shown its appeal as a sensitive technique for in vivo whole body optical imaging. However, the development of injectable tumor-specific near-infrared fluorescent (NIRF) probes makes fluorescence imaging (FLI) a promising alternative to BLI in situations where BLI ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Bang-Wen, Mol, Isabel M., Keereweer, Stijn, van Beek, Ermond R., Que, Ivo, Snoeks, Thomas J. A., Chan, Alan, Kaijzel, Eric L., Löwik, Clemens W. G. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278453/
https://www.ncbi.nlm.nih.gov/pubmed/22348134
http://dx.doi.org/10.1371/journal.pone.0031875
_version_ 1782223576506564608
author Xie, Bang-Wen
Mol, Isabel M.
Keereweer, Stijn
van Beek, Ermond R.
Que, Ivo
Snoeks, Thomas J. A.
Chan, Alan
Kaijzel, Eric L.
Löwik, Clemens W. G. M.
author_facet Xie, Bang-Wen
Mol, Isabel M.
Keereweer, Stijn
van Beek, Ermond R.
Que, Ivo
Snoeks, Thomas J. A.
Chan, Alan
Kaijzel, Eric L.
Löwik, Clemens W. G. M.
author_sort Xie, Bang-Wen
collection PubMed
description Bioluminescence imaging (BLI) has shown its appeal as a sensitive technique for in vivo whole body optical imaging. However, the development of injectable tumor-specific near-infrared fluorescent (NIRF) probes makes fluorescence imaging (FLI) a promising alternative to BLI in situations where BLI cannot be used or is unwanted (e.g., spontaneous transgenic tumor models, or syngeneic mice to study immune effects). In this study, we addressed the questions whether it is possible to detect tumor progression using FLI with appropriate sensitivity and how FLI correlates with BLI measurements. In addition, we explored the possibility to simultaneously detect multiple tumor characteristics by dual-wavelength FLI (∼700 and ∼800 nm) in combination with spectral unmixing. Using a luciferase-expressing 4T1-luc2 mouse breast cancer model and combinations of activatable and targeting NIRF probes, we showed that the activatable NIRF probes (ProSense680 and MMPSense680) and the targeting NIRF probes (IRDye 800CW 2-DG and IRDye 800CW EGF) were either activated by or bound to 4T1-luc2 cells. In vivo, we implanted 4T1-luc2 cells orthotopically in nude mice and were able to follow tumor progression longitudinally both by BLI and dual-wavelength FLI. We were able to reveal different probe signals within the tumor, which co-localized with immuno-staining. Moreover, we observed a linear correlation between the internal BLI signals and the FLI signals obtained from the NIRF probes. Finally, we could detect pulmonary metastases both by BLI and FLI and confirmed their presence histologically. Taken together, these data suggest that dual-wavelength FLI is a feasible approach to simultaneously detect different features of one tumor and to follow tumor progression with appropriate specificity and sensitivity. This study may open up new perspectives for the detection of tumors and metastases in various experimental models and could also have clinical applications, such as image-guided surgery.
format Online
Article
Text
id pubmed-3278453
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-32784532012-02-17 Dual-Wavelength Imaging of Tumor Progression by Activatable and Targeting Near-Infrared Fluorescent Probes in a Bioluminescent Breast Cancer Model Xie, Bang-Wen Mol, Isabel M. Keereweer, Stijn van Beek, Ermond R. Que, Ivo Snoeks, Thomas J. A. Chan, Alan Kaijzel, Eric L. Löwik, Clemens W. G. M. PLoS One Research Article Bioluminescence imaging (BLI) has shown its appeal as a sensitive technique for in vivo whole body optical imaging. However, the development of injectable tumor-specific near-infrared fluorescent (NIRF) probes makes fluorescence imaging (FLI) a promising alternative to BLI in situations where BLI cannot be used or is unwanted (e.g., spontaneous transgenic tumor models, or syngeneic mice to study immune effects). In this study, we addressed the questions whether it is possible to detect tumor progression using FLI with appropriate sensitivity and how FLI correlates with BLI measurements. In addition, we explored the possibility to simultaneously detect multiple tumor characteristics by dual-wavelength FLI (∼700 and ∼800 nm) in combination with spectral unmixing. Using a luciferase-expressing 4T1-luc2 mouse breast cancer model and combinations of activatable and targeting NIRF probes, we showed that the activatable NIRF probes (ProSense680 and MMPSense680) and the targeting NIRF probes (IRDye 800CW 2-DG and IRDye 800CW EGF) were either activated by or bound to 4T1-luc2 cells. In vivo, we implanted 4T1-luc2 cells orthotopically in nude mice and were able to follow tumor progression longitudinally both by BLI and dual-wavelength FLI. We were able to reveal different probe signals within the tumor, which co-localized with immuno-staining. Moreover, we observed a linear correlation between the internal BLI signals and the FLI signals obtained from the NIRF probes. Finally, we could detect pulmonary metastases both by BLI and FLI and confirmed their presence histologically. Taken together, these data suggest that dual-wavelength FLI is a feasible approach to simultaneously detect different features of one tumor and to follow tumor progression with appropriate specificity and sensitivity. This study may open up new perspectives for the detection of tumors and metastases in various experimental models and could also have clinical applications, such as image-guided surgery. Public Library of Science 2012-02-13 /pmc/articles/PMC3278453/ /pubmed/22348134 http://dx.doi.org/10.1371/journal.pone.0031875 Text en Xie et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Xie, Bang-Wen
Mol, Isabel M.
Keereweer, Stijn
van Beek, Ermond R.
Que, Ivo
Snoeks, Thomas J. A.
Chan, Alan
Kaijzel, Eric L.
Löwik, Clemens W. G. M.
Dual-Wavelength Imaging of Tumor Progression by Activatable and Targeting Near-Infrared Fluorescent Probes in a Bioluminescent Breast Cancer Model
title Dual-Wavelength Imaging of Tumor Progression by Activatable and Targeting Near-Infrared Fluorescent Probes in a Bioluminescent Breast Cancer Model
title_full Dual-Wavelength Imaging of Tumor Progression by Activatable and Targeting Near-Infrared Fluorescent Probes in a Bioluminescent Breast Cancer Model
title_fullStr Dual-Wavelength Imaging of Tumor Progression by Activatable and Targeting Near-Infrared Fluorescent Probes in a Bioluminescent Breast Cancer Model
title_full_unstemmed Dual-Wavelength Imaging of Tumor Progression by Activatable and Targeting Near-Infrared Fluorescent Probes in a Bioluminescent Breast Cancer Model
title_short Dual-Wavelength Imaging of Tumor Progression by Activatable and Targeting Near-Infrared Fluorescent Probes in a Bioluminescent Breast Cancer Model
title_sort dual-wavelength imaging of tumor progression by activatable and targeting near-infrared fluorescent probes in a bioluminescent breast cancer model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278453/
https://www.ncbi.nlm.nih.gov/pubmed/22348134
http://dx.doi.org/10.1371/journal.pone.0031875
work_keys_str_mv AT xiebangwen dualwavelengthimagingoftumorprogressionbyactivatableandtargetingnearinfraredfluorescentprobesinabioluminescentbreastcancermodel
AT molisabelm dualwavelengthimagingoftumorprogressionbyactivatableandtargetingnearinfraredfluorescentprobesinabioluminescentbreastcancermodel
AT keereweerstijn dualwavelengthimagingoftumorprogressionbyactivatableandtargetingnearinfraredfluorescentprobesinabioluminescentbreastcancermodel
AT vanbeekermondr dualwavelengthimagingoftumorprogressionbyactivatableandtargetingnearinfraredfluorescentprobesinabioluminescentbreastcancermodel
AT queivo dualwavelengthimagingoftumorprogressionbyactivatableandtargetingnearinfraredfluorescentprobesinabioluminescentbreastcancermodel
AT snoeksthomasja dualwavelengthimagingoftumorprogressionbyactivatableandtargetingnearinfraredfluorescentprobesinabioluminescentbreastcancermodel
AT chanalan dualwavelengthimagingoftumorprogressionbyactivatableandtargetingnearinfraredfluorescentprobesinabioluminescentbreastcancermodel
AT kaijzelericl dualwavelengthimagingoftumorprogressionbyactivatableandtargetingnearinfraredfluorescentprobesinabioluminescentbreastcancermodel
AT lowikclemenswgm dualwavelengthimagingoftumorprogressionbyactivatableandtargetingnearinfraredfluorescentprobesinabioluminescentbreastcancermodel